Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 117.12 -1.18% -1.40
ALXN closed down 2.03 percent on Wednesday, November 14, 2018, on 67 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ALXN trend table...

Date Alert Name Type % Chg
Nov 14 20 DMA Resistance Bearish 0.87%
Nov 14 MACD Bearish Signal Line Cross Bearish 0.87%
Nov 14 Multiple of Ten Bearish Other 0.87%
Nov 14 Down 3 Days in a Row Weakness 0.87%
Nov 14 Down 4 Days in a Row Weakness 0.87%
Nov 13 200 DMA Resistance Bearish -1.18%
Nov 13 20 DMA Resistance Bearish -1.18%
Nov 13 Multiple of Ten Bearish Other -1.18%
Nov 13 Down 3 Days in a Row Weakness -1.18%
Nov 12 Fell Below 200 DMA Bearish -1.25%

Older signals for ALXN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Is ALXN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 140.77
52 Week Low 102.1
Average Volume 1,631,944
200-Day Moving Average 120.8359
50-Day Moving Average 123.658
20-Day Moving Average 120.1145
10-Day Moving Average 121.998
Average True Range 4.8924
ADX 21.41
+DI 16.4797
-DI 27.1776
Chandelier Exit (Long, 3 ATRs ) 114.8928
Chandelier Exit (Short, 3 ATRs ) 124.4172
Upper Bollinger Band 130.3563
Lower Bollinger Band 109.8727
Percent B (%b) 0.3
BandWidth 17.053395
MACD Line -1.1176
MACD Signal Line -1.0749
MACD Histogram -0.0428
Fundamentals Value
Market Cap 25.92 Billion
Num Shares 223 Million
EPS 2.31
Price-to-Earnings (P/E) Ratio 50.26
Price-to-Sales 8.25
Price-to-Book 3.18
PEG Ratio 1.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 124.33
Resistance 3 (R3) 124.99 122.90 122.96
Resistance 2 (R2) 122.90 120.81 122.58 122.50
Resistance 1 (R1) 119.51 119.52 118.47 118.85 122.05
Pivot Point 117.42 117.42 116.90 117.10 117.42
Support 1 (S1) 114.03 115.33 112.99 113.37 110.17
Support 2 (S2) 111.94 114.04 111.62 109.72
Support 3 (S3) 108.55 111.94 109.26
Support 4 (S4) 107.89